Toby Maher on ENV-101 in patients with idiopathic pulmonary fibrosis
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
Toby Maher on ENV-101 in patients with idiopathic pulmonary fibrosis
-
Narrated by:
-
By:
Summary
Toby Maher joins us to discuss results of a randomised, double-blind, placebo-controlled, proof-of-concept trial of ENV-101, an oral inhibitor of the hedgehog signalling pathway, in patients with idiopathic pulmonary fibrosis.
Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00239-5/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanres
Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
adbl_web_anon_alc_button_suppression_c
No reviews yet